James Pearson

BCHC Community Connexions. We remain deeply appreciative of the £2,000 contribution received, from The ELSA study @elsadiabetes who had taken on fundraising challenges, which will support @BCHC_CommCX in organising approximately 2–3 further Community Clinics.

Meet the team behind the ELSA study: Consultant receives national recognition for leading pioneering T1D research @uhbtrust @unibirmingham @parthnarendran @RenukaDias @JAPearsonLab uhb.nhs.uk/news-and-event…

the ELSA study team Celebrated RCP Excellence in Patient Care Awards, these awards celebrate the outstanding contributions of RCP members and fellows worldwide, who are driving improvements in patient care through education, clinical practice, research and policy. @unibirmingham

Still 6 weeks left to join our “SMART” study if you have type 1 diabetes and are aged 18-50! See below for a full list of research opportunities…

@elsadiabetes 🧑🏻‍🔬

#WorldEmojiDay! 🥽🧫 Here's a challenge for you, could you describe your job using only emojis? We'll go first... 🔬🧬💊💉 Now it's your turn! Describe your job using only emojis in the replies. No words allowed! 👇

Last month the NHS announced the approval of Teplizumab which is the first immunotherapy for #T1D & has been shown to delay onset. Part of this is finding people at risk. That’s where @T1DRA comes in – Sign up today to find out your risk of developing type 1 diabetes

Understanding T1D Burnout: National Survey: Before you decide whether or not to take part, it is important for you to understand why the research is being done and what it will involve 👇 click on link app.onlinesurveys.jisc.ac.uk/s/socs/t1dburn… @JAPearsonLab @T1DRAdiabetes @parthnarendran

Thank you to all the researchers improving the lives of people living with, or at risk of, Type 1 diabetes

A day where we celebrate the work of the ELSA study researchers making a difference to people's lives, not just in Birmingham but the UK. @unibirmingham @parthnarendran @RenukaDias @T1DRAdiabetes @BristolUni @BT1DUK @DiabetesUK @JAPearsonLab @AlexRichter3

Research Appreciation Day: Medical science has proven time and again that when the resources are provided, great progress in the treatment, cure, and prevention of disease can occur. @BirminghamBRC @unibirmingham @parthnarendran @BT1DUK @DiabetesUK @RenukaDias @JAPearsonLab 👩‍🔬🔬

Research Appreciation Day 5th July: Behind every medical breakthrough is a team of dedicated health researchers. Thank you for your tireless fight to improve lives and bring hope to patients worldwide. @T1DRAdiabetes @parthnarendran @unibirmingham @NIHRresearch 👩‍🔬🩸🔬💊

@T1DRAdiabetes (ages 8-70) & @elsadiabetes (ages 2-17) are the only studies screening for #T1D risk autoantibodies in the UK. With the recent approval of Teplizumab, this is more important than ever. Sign up today to find out your eligibility for clinical trials/Tzield treatment

“Yesterday's landmark approval of teplizumab marks the start of a new age of type 1 diabetes treatment. “For the first time in 100 years, we are moving beyond insulin, with a medicine that targets the root cause of the condition.” Do you have any questions for the team

Today, history has been made: NICE has approved teplizumab for use on the NHS in England and Wales. Teplizumab is the first ever immunotherapy that can delay the onset of type 1 diabetes symptoms for people in the early stages of the condition. For the first time, we’re not just managing type 1 - we’re changing its course. This milestone means many things. But above all, it means time. More time to simply be a child. A reduction in emergency diagnoses and serious complications like diabetic ketoacidosis. A softer landing for individuals and families suddenly facing management of a life-long condition, and with it, renewed hope for the future. And this achievement belongs to you, our community. Breakthrough T1D funded early-stage research and the clinical trials that made teplizumab a reality. This breakthrough was made possible by your belief and support. Together, we are changing what’s possible. 💙 Read the full story here: bit.ly/4oJQzoo #GBDoc #Type1Diabetes #Teplizumab

A hugely exciting day - Teplizumab has been approved for use in early stage Type 1 diabetes aimed at delaying progression to insulin start. A step change in how we manage Type 1 diabetes and first new drug in over 100 years. Moving us towards insulin free Type 1 Diabetes 1/2

We're tipping into a new era for type 1 diabetes. For the first time, a treatment to slow down the development of type 1 in its early stages will be available on the NHS. Today's decision from NICE means NHS England has 90 days to put services in place to deliver teplizumab.

Can you help: about 75% of current T1DRA participants are women, researchers are actively urging more men across the UK to step forward to be screened for T1D Sign up: t1dra.bristol.ac.uk/ready-to-conse… @triggersbroom17 @diabetes_chat @T1DRAdiabetes are you male 18-70yrs T1DRA needs you

A great study participant perspective on my colleague Dr Danijela Tatovic’s SMART study @unibirmingham @UoBmedicalsci testing whether we can boost the Tregs that naturally protect the insulin-producing cells in Type 1 diabetes

There's still time to take part in this study 👇

What a fantastic meeting sharing best practices around how to implement general population screening for T1D. I’m lucky enough to work with some fantastic people raising the T1D screening profile within the @elsadiabetes and @T1DRAdiabetes studies